Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.6090
-0.0333-5.18%
Volume:436.86K
Turnover:268.14K
Market Cap:24.05M
PE:-0.32
High:0.6486
Open:0.6486
Low:0.6000
Close:0.6423
52wk High:5.14
52wk Low:0.4300
Shares:39.50M
Float Shares:30.75M
Volume Ratio:0.84
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9003
EPS(LYR):-1.6652
ROE:-101.55%
ROA:-55.53%
PB:0.47
PE(LYR):-0.37

Loading ...

Vistagen Announces Topline Results From Palisade-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Dec 17, 2025

Vistagen Therapeutics Inc - Study Did Not Show Significant Improvement in Anxiety Reduction

THOMSON REUTERS
·
Dec 17, 2025

Vistagen Therapeutics Inc - Cash Preservation Measures Expected to Provide Runway Into 2027

THOMSON REUTERS
·
Dec 17, 2025

Vistagen Therapeutics Inc - Favorable Safety Data of Fasedienol Consistent With Previous Trials

THOMSON REUTERS
·
Dec 17, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM

Reuters
·
Dec 17, 2025

VistaGen Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Financial Officer Nick B. Tressler

Reuters
·
Dec 04, 2025

BRIEF-Vistagen Appoints Nick Tressler As Chief Financial Officer

Reuters
·
Dec 01, 2025

Vistagen Appoints Nick Tressler as Chief Financial Officer

THOMSON REUTERS
·
Dec 01, 2025

Vistagen presents exploratory PH80 data at Menopause Society meeting

TIPRANKS
·
Nov 26, 2025

VistaGen Unveils Rapid-Acting PH80 Nasal Spray Data for Menopausal Hot Flashes at Menopause Society Meeting

Reuters
·
Nov 26, 2025

VistaGen Q2 EPS USD -0.54

Reuters
·
Nov 20, 2025

VistaGen Therapeutics: Buy Rating Backed by Promising Clinical Trials and Stable Financial Outlook

TIPRANKS
·
Nov 15, 2025

VistaGen Therapeutics: Buy Rating Affirmed Amid Promising Fasedienol Trials and Market Potential

TIPRANKS
·
Nov 14, 2025

Biopharmaceutical firm VistaGen's fiscal Q2 net loss widens

Reuters
·
Nov 14, 2025

BRIEF-VistaGen Q2 EPS USD -0.54

Reuters
·
Nov 14, 2025

VistaGen Therapeutics reports fiscal Q2 net loss and higher R&D expenses

Reuters
·
Nov 14, 2025

Press Release: Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Dow Jones
·
Nov 10, 2025

VistaGen Therapeutics Inc. to Release Fiscal Year 2026 Second Quarter Results

Reuters
·
Nov 10, 2025

VistaGen Therapeutics CEO to Join Stifel Healthcare Conference Fireside Chat

Reuters
·
Nov 05, 2025

VistaGen Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Paul R. Edick

Reuters
·
Nov 05, 2025